You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease

https://doi.org/10.1136/ebm.11.2.47

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr J A Dormandy, St. George’s Hospital, UK. john.dormandy{at}btinternet.com

    • Sources of funding: Takeda Pharmaceutical Company and Eli Lily and Company.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 63a-63a Published Online First: 30 Mar 2006. doi: 10.1136/ebm.11.2.63a